{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T22:09:58Z","timestamp":1777500598778,"version":"3.51.4"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011719","name":"Bone Cancer Research Trust","doi-asserted-by":"publisher","award":["BCRT\/34\/13"],"award-info":[{"award-number":["BCRT\/34\/13"]}],"id":[{"id":"10.13039\/100011719","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical and Biophysical Research Communications"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.bbrc.2019.07.047","type":"journal-article","created":{"date-parts":[[2019,7,27]],"date-time":"2019-07-27T07:16:22Z","timestamp":1564211782000},"page":"383-389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["TRAIL responses are enhanced by nuclear export inhibition in osteosarcoma"],"prefix":"10.1016","volume":"517","author":[{"given":"K.L.","family":"Phillips","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.A.","family":"Cross","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbrc.2019.07.047_bib1","doi-asserted-by":"crossref","first-page":"E508","DOI":"10.1002\/ijc.26426","article-title":"Incidence and survival of malignant bone sarcomas in England 1979-2007","volume":"131","author":"Whelan","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2019.07.047_bib2","first-page":"5","author":"Bielack","year":"2016","journal-title":"Advances in the management of osteosarcoma"},{"key":"10.1016\/j.bbrc.2019.07.047_bib3","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.ctrv.2006.12.007","article-title":"Survival from adolescent cancer","volume":"33","author":"Desandes","year":"2007","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.bbrc.2019.07.047_bib4","article-title":"Induction of apoptosis by APO-2 ligand, a new member of the TNF cytokine family","volume":"10","author":"Ashkenazi","year":"1996","journal-title":"FASEB J."},{"key":"10.1016\/j.bbrc.2019.07.047_bib5","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.277.5327.815","article-title":"An antagonist decoy receptor and a death domain-containing receptor for TRAIL","volume":"277","author":"Pan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2019.07.047_bib6","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1126\/science.277.5327.818","article-title":"Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors","volume":"277","author":"Sheridan","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.bbrc.2019.07.047_bib7","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1074\/jbc.273.23.14363","article-title":"Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL","volume":"273","author":"Emery","year":"1998","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.bbrc.2019.07.047_bib8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1038\/sj.leu.2404518","article-title":"Agonists of TRAIL death receptors induce myeloma cell apoptosis that is not prevented by cells of the bone marrow microenvironment","volume":"21","author":"Locklin","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.bbrc.2019.07.047_bib9","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1002\/cncr.28353","article-title":"TRAIL receptor agonist conatumumab with modified FOLFOX6 plus bevacizumab for first-line treatment of metastatic colorectal cancer","volume":"119","author":"Fuchs","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bbrc.2019.07.047_bib10","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.lungcan.2013.09.014","article-title":"A\u00a0randomized, double-blind, placebo-controlled phase 2 study of tigatuzumab (CS-1008) in combination with carboplatin\/paclitaxel in patients with chemotherapy-naive metastatic\/unresectable non-small cell lung cancer","volume":"82","author":"Reck","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.bbrc.2019.07.047_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/nature08012","article-title":"Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis","volume":"459","author":"Spencer","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.bbrc.2019.07.047_bib12","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/jcb.21721","article-title":"Phenotypic variations of TRAIL sensitivity in cloned populations of prostate cancer cells","volume":"104","author":"Cross","year":"2008","journal-title":"J.\u00a0Cell. Biochem."},{"key":"10.1016\/j.bbrc.2019.07.047_bib13","first-page":"229","article-title":"The expression of CRM1 is associated with prognosis in human osteosarcoma","volume":"21","author":"Yao","year":"2009","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbrc.2019.07.047_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40164-015-0002-5","article-title":"Selective inhibitors of nuclear export (SINE) in hematological malignancies","volume":"4","author":"Das","year":"2015","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2019.07.047_bib15","article-title":"Selective inhibitors of nuclear export (SINE)- a novel class of anti-cancer agents","volume":"7","author":"Parikh","year":"2014","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2019.07.047_bib16","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/pros.10197","article-title":"Leptomycin B stabilizes and activates p53 in primary prostatic epithelial cells and induces apoptosis in the LNCaP cell line","volume":"54","author":"Lecane","year":"2003","journal-title":"The Prostate"},{"key":"10.1016\/j.bbrc.2019.07.047_bib17","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/ijc.22591","article-title":"Selective induction of apoptosis by leptomycin B in keratinocytes expressing HPV oncogenes","volume":"120","author":"Gray","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2019.07.047_bib18","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1038\/bjc.1996.415","article-title":"Phase I trial of elactocin","volume":"74","author":"Newlands","year":"1996","journal-title":"Br. J. Canc."},{"key":"10.1016\/j.bbrc.2019.07.047_bib19","article-title":"Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K\/mTOR inhibition","volume":"12","author":"Fourneaux","year":"2019","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.bbrc.2019.07.047_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/srep27878","article-title":"Aldh1 expression and activity increase during tumor evolution in sarcoma cancer stem cell populations","volume":"6","author":"Martinez-Cruzado","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2019.07.047_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013943","article-title":"High ALDH activity identifies chemotherapy-resistant ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition","volume":"5","author":"Awad","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.bbrc.2019.07.047_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4236\/jct.2014.54040","article-title":"ALDH activity correlates with metastatic potential in primary sarcomas of bone","volume":"5","author":"Greco","year":"2014","journal-title":"J.\u00a0Cancer Ther."},{"key":"10.1016\/j.bbrc.2019.07.047_bib23","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/ijc.25331","article-title":"Prospective identification of tumorigenic osteosarcoma cancer stem cells in OS99-1 cells based on high aldehyde dehydrogenase activity","volume":"128","author":"Wang","year":"2011","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bbrc.2019.07.047_bib24","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2002-09-2975","article-title":"The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP","volume":"102","author":"Sayers","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bbrc.2019.07.047_bib25","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.yexcr.2017.09.012","article-title":"SAHA-induced TRAIL-sensitisation of Multiple Myeloma cells is enhanced in 3D cell culture","volume":"360","author":"Arhoma","year":"2017","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.bbrc.2019.07.047_bib26","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.2174\/092986708786242859","article-title":"CRM1-Mediated nuclear export of proteins and drug resistance in cancer","volume":"15","author":"Turner","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbrc.2019.07.047_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbrc.2019.07.047_bib28","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2018.03.003","article-title":"Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma","volume":"18","author":"Gandhi","year":"2018","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.bbrc.2019.07.047_bib29","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.1038\/sj.onc.1203260","article-title":"Effects on normal fibroblasts and neuroblastoma cells of the activation of the p53 response by the nuclear export inhibitor leptomycin B","volume":"18","author":"Smart","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2019.07.047_bib30","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-42450-0","article-title":"p27\/Kip 1 functions as a tumor suppressor and oncoprotein in osteosarcoma","volume":"9","author":"Currier","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbrc.2019.07.047_bib31","doi-asserted-by":"crossref","first-page":"78883","DOI":"10.18632\/oncotarget.12428","article-title":"Selinexor, a Selective Inhibitor of Nuclear Export (SINE) compound, acts through NF-kappa B deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death","volume":"7","author":"Kashyap","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbrc.2019.07.047_bib32","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1038\/sj.onc.1204570","article-title":"NF-kappa B activation results in rapid inactivation of JNK in TNF alpha-treated Ewing sarcoma cells: a mechanism for the anti-apoptotic effect of NF-kappa B","volume":"20","author":"Javelaud","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.bbrc.2019.07.047_bib33","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/480713","article-title":"Rapamycin inhibits ALDH activity, resistance to oxidative stress, and metastatic potential in murine osteosarcoma cells","volume":"2013","author":"Mu","year":"2013","journal-title":"Sarcoma"},{"key":"10.1016\/j.bbrc.2019.07.047_bib34","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1158\/0008-5472.CAN-08-0858","article-title":"Identification of nuclear export inhibitors with potent anticancer activity in\u00a0vivo","volume":"69","author":"Mutka","year":"2009","journal-title":"Cancer Res."}],"container-title":["Biochemical and Biophysical Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1931397X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006291X1931397X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T15:14:57Z","timestamp":1777389297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006291X1931397X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0006291X1931397X"],"URL":"https:\/\/doi.org\/10.1016\/j.bbrc.2019.07.047","relation":{},"ISSN":["0006-291X"],"issn-type":[{"value":"0006-291X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"TRAIL responses are enhanced by nuclear export inhibition in osteosarcoma","name":"articletitle","label":"Article Title"},{"value":"Biochemical and Biophysical Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbrc.2019.07.047","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}